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Abstracts / Osteoarthritis and Cartilage 21 (2013) S63–S312 S285between N/R and I areas were identiﬁed. Many inﬂammatory mediators
appear differentially expressed. The interferon alpha-inductible protein
6 (IFI6) was the most up-regulated. We also identiﬁed the hydrox-
ysteroid (11-beta) dehydrogenase 1 (HSD11B1), the cathepsin K (CTSK),
the chemokine (C-X-C motif) ligand 1 (CXCL1) and the EBV-induced G-
protein coupled receptor 2 (EBI2). The differential expression of inter-
mediates involved in angiogenesis pathway was also revealed between
N/R and I areas. Among them, R-spondin-3 (RSPO3), the secreted
phopshoprotein 1 (SPP1) and aquaporin 9 (AQP9) were up-regulated
whereas ADAMTS1 was down-regulated. Finally, in the Wnt signaling,
RSPO3 was up-regulated unlike dickkopf homolog 3 (DKK3) which was
in turn down-regulated. We next performed a class comparison test
between N/R and N/R-CS in one hand and between I and I-CS the other
hand. 489 genes were identiﬁed as differentially expressed genes
between N/R and N/R-CS conditions while 219 genes were identiﬁed
between I and I-CS conditions. In this latter, our attention was focused
on the down-regulated genes. Among them, we identiﬁed a number
implicated in angiogenesis and cell migration pathways. Thus, the
endothelial cell-speciﬁc molecule-1 (ESM1), the Transmembrane-4-L-
six-family-1 (TM4SF1), the 50-Ectonucleotidase (NT5E) and the growth
arrest-speciﬁc gene 6 (GAS6) were down-regulated by CS.
Conclusions: Our work demonstrates the differential gene expression
proﬁle between paired inﬂammatory and normal/reactive areas of
synovial membrane as well as the modulatory effects of CS on gene
expression in the inﬂammatory areas, especially regarding genes
involved in both angiogenesis and cell migration.
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INVESTIGATION OF POTENTIAL NEW TARGETS FOR THE DIAGNOSIS
AND/OR THE TREATMENT OF OSTEOARTHRITIS
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Purpose: Synovial inﬂammation plays a key role in the pathophysiology
process of osteoarthritis (OA). We have previously compared the gene
expression pattern of synovial cells isolated from inﬂammatory (I) or
normal/reactive (N/R) areas of a synovial membrane harvested from the
same OA patient. We identiﬁed a large number of mediators belonging
to key pathways involved in OA pathogenesis. The aim of this study was
to validate different potential new targets for the diagnosis and/or the
treatment OA.
Methods: Synovial cells (SC) were isolated from synovial specimens
obtained from OA patients undergoing knee replacement. The inﬂam-
matory status of the synovial membranewas characterized according to
macroscopic criteria. The biopsies from N/R and I areas were cultured
separately for a period of 7 days. Microarray gene expression proﬁling
between N/R and I areas was performed. The biological relevance of up-
and down-regulated genes was analyzed with Ingenuity Pathways
Analysis. Western blot and immunohistochemistry conﬁrmed the
identiﬁed genes most differentially expressed in the key pathways. The
production of the triggering receptor expressed on myeloid cells-1
(TREM1), the alarmin S100 calcium binding protein A9 (S100A9), the
wingless-type MMTV integration site family, member 5A (Wnt-5A) and
the stanniocalcin 1 (STC1) were evaluated by Western blot. S100A9,
hyaluronan synthase-1 (HAS1) and STC1 expression and localization
were investigated by immunohistochemistry.
Results: 896 genes differentially expressed in N/R and I areas were iden-
tiﬁed. The key pathways were related to inﬂammation, cartilage metab-
olism,Wnt signaling and angiogenesis. In the inﬂammatory gene pattern,
TREM1 and S100A9 were strongly upregulated. We validated the
production of these proteins in OA synovial biopsies by Western blot.
TREM1 and S100A9 were increased in I compared to N/R synovial cells
culture. S100A9 was observed in the perivascular area and in sublining
cells in I synovial biopsies, but not in N/R biopsies. An increased staining
was also observed in the intima lining layer of I when compared to N/R
biopsies. The most upregulated anabolism enzyme in I synovial biopsies
was HAS1. Using immunohistochemistry, we observed in I areas an
increase of the HAS1-positive cells mainly in the intima lining. We also
studied the protein production of Wnt-5A, the most upregulated inter-
mediate of Wnt signaling pathway. The protein level was increased in I
compared toN/R areas. Finally, in the angiogenesis pathway, one themostupregulated genewas STC1. A signiﬁcant increase of STC1 productionwas
observed in I areas compared toN/R areas byWestern blot. This resultwas
also supported by the immunohistochemical analysis. In I area, the
staining for STC1 was more intense in perivascular and sublining cells.
Conclusions: Synovial membrane inﬂammation is a key target for OA
treatments. In this work, we have identiﬁed proteins involved in the
synovitis pathways like angiogenesis, cells inﬁltration and matrix
remodeling. These proteins could be targeted by drugs and used as
companion biomarkers for evaluating their efﬁcacy. Although qualita-
tive, our results could also yield to the identiﬁcation of markers of the
disease. This investigation has to be further pursued.
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CHONDROITIN SULFATE REGULATES TWO ANTI-ANGIOGENIC
FACTORS IN HUMAN OSTEOARTHRITIC SYNOVIAL FIBROBLASTS
J.Martel-Pelletier y, F.Mineau y, E.Montell z, J. Vergés z, J.-P. Pelletier y. yUniv.
of Montreal Hosp. Res. Ctr. (CRCHUM), Montreal, QC, Canada; z Pre-Clinical
R&D Area, Pharma Sci. Div., Bioibérica S.A., Barcelona, Spain
Purpose: The symptomatic slow acting drug for osteoarthritis (SYSA-
DOA), chondroitin sulfate, has attracted much interest as a biological
agent for its use in the effective relief of disease symptoms. This is likely
due to its capacity for reducing joint swelling and effusion which may
be explained by its anti-inﬂammatory effects. However, the factors
involved in this latter effect are yet to be fully identiﬁed. Angiogenesis is
an important event of synovial inﬂammation and it is suggested to
contribute to the joint symptoms in OA. We thus elected to determine
the effect of chondroitin sulfate on the levels of two well-known anti-
angiogenic factors previously demonstrated to be involved in OA: the
vascular endothelial growth inhibitor (VEGI) and thrombospondin-1
(TSP-1). Furthermore, we explored the signaling pathways by which
chondroitin sulfate exerts its effects on these factors.
Methods: Human OA synovial ﬁbroblasts were obtained from sequen-
tial enzymatic digestion. Cells were pre-incubated for 18 hours with
chondroitin sulfate (200 mg/ml; CSbBio-Active, Bioibérica, Spain) and
then incubated with IL-1ß (10 and 100 pg/ml) in the absence or pres-
ence of chondroitin sulfate for increasing periods of time. Cells were
processed for protein expression determination using quantitative PCR,
protein production using ELISAs, and for signaling pathways using
Western blotting.
Results: Both VEGI and TSP-1 expression were dose-dependently
decreased by IL-1ß at both concentrations tested. Chondroitin sulfate
signiﬁcantly increased the expression and synthesis levels of the two
anti-angiogenic factors VEGI and TSP-1 under basal conditions as well
as under IL-1ß treatment. The signaling pathways through which
chondroitin sulfate increased the levels of VEGI and TSP-1 in the pres-
ence of IL-1ß were further investigated by measuring the phosphory-
lated levels of three MAP kinases, namely ERK1/2, p38, and JNK, and
other cascades including NF-kB, Akt, and STAT-3. Data revealed that the
effects occurred through two main pathways, Akt and STAT-3. Addi-
tional experiments with speciﬁc inhibitors of Akt phosphorylation (SH-
6, Santa Cruz) and STAT-3 translocation (Stat3 inhibitor VIII, 5,15-DPP,
Santa Cruz) conﬁrmed these data.
Conclusions: This study showed that chondroitin sulfate increased the
levels of two important anti-angiogenic factors, which could provide
a possible new mechanism of action of this SYSADOA. These ﬁndings
may explain, in part, how chondroitin sulfate reduces the severity of
synovitis in knee OA. In addition, these data bring to light that anti-
angiogenic factors could be targeted as a speciﬁc therapeutic approach
in disease modifying OA drug development.
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GENE EXPRESSION ANALYSIS OF OA SYNOVIUM REVEALS ELEVATION
OF TGF-ß RESPONSIVE GENES IN OA-RELATED FIBROSIS
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Purpose: Synovial ﬁbrosis is a major contributor to joint stiffness in
osteoarthritis (OA). We have previously shown that TGF-b, which is
elevated inOA,playsakey role inonsetandpersistenceof synovialﬁbrosis.
Blocking TGF-b as a therapeutic intervention for ﬁbrosis in OA is not an
option, as TGF-b is crucial for cartilage maintenance and repair. To over-
come this problem and ﬁnd a target that can be blocked we wanted to
